Close this search box.
Close this search box.
With sepsis, every hour counts
Target therapy sooner, with species identification before the second dose of empiric therapy

T2Bacteria and T2Candida are the first and only FDA-cleared diagnostic tests to provide species identification of sepsis-causing bacterial and fungal pathogens, directly from a whole blood sample, independent of a positive blood culture.

T2Biothreat Panel: Now FDA-cleared
T2Biothreat has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)

The T2Biothreat Panel is a direct-from-blood molecular diagnostic test that runs on the FDA-cleared T2Dx® Instrument and simultaneously detects six biothreat pathogens.

Enhancing the standard of care.

With T2 Biosystems, hospitals can identify sepsis-causing pathogens faster and more accurately than the standard of blood culture alone

Hospitals trust in T2MR Technology

Demonstrated 47% reduction in antifungal therapy.
Henry Ford Health System
Realized 7 days reduction in median length of stay in the ICU.
Lee Health
T2Bacteria positive results 20 hours sooner than blood culture.
Huntsville Hospital
Saved ~$280 pharmacy costs per patient.
Robert Wood Johnson Medical School
Identified escalation and de-escalation opportunities in patients tested with T2Candida.
Riverside Community Hospital
100% of patients who tested positive received appropriate therapy in <9 hours

Patient Case Studies

Real stories about the positive impact of T2 Biosystems on clinical decisions and outcomes

Numbers don't lie.

Sepsis is a burden on healthcare and patients, contributing to:

1 in 3
1 in 2-3
US hospital deaths.
11 million
deaths annually, worldwide.
$62 billion
in US healthcare costs.
Integrate T2 Biosystems panels into your hospital today!